Indian Immunologicals denies making NSQ anti-rabies vaccine vials

Indian Immunologicals Limited has distanced itself from Abhayrab anti-rabies vaccine vials that were declared not suitable for quality (NSQ) and flagged as misbranded by a government testing laboratory. The company stated that the problematic vials were not manufactured by its human health division, suggesting the products may have originated from another source or manufacturer.

The declaration of NSQ status indicates the vaccine batches failed to meet required quality standards during laboratory testing. Misbranding allegations further suggest the vials may have carried incorrect labeling or packaging information. Such quality failures raise concerns about product authenticity and safety in the anti-rabies vaccine supply chain.

Indian Immunologicals' clarification comes as regulatory scrutiny intensifies around pharmaceutical manufacturing and quality assurance. The company's statement suggests the need for thorough investigation into the source of the defective vials and how they entered circulation in the Indian market.

Anti-rabies vaccines are critical public health commodities, with any quality compromise posing serious risks to patients relying on these life-saving treatments. Authorities are expected to trace the origin of the NSQ vials and take appropriate action against responsible parties to prevent similar incidents.